Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Stoke Therapeutics (STOK) Capital Expenditures (2022 - 2025)

Historic Capital Expenditures for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $132000.0.

  • Stoke Therapeutics' Capital Expenditures rose 2815.53% to $132000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $480000.0, marking a year-over-year increase of 2307.69%. This contributed to the annual value of $203000.0 for FY2024, which is 8743.81% down from last year.
  • Per Stoke Therapeutics' latest filing, its Capital Expenditures stood at $132000.0 for Q3 2025, which was up 2815.53% from $154000.0 recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Capital Expenditures high stood at $2.0 million for Q3 2022, and its period low was $12000.0 during Q1 2024.
  • In the last 4 years, Stoke Therapeutics' Capital Expenditures had a median value of $229000.0 in 2023 and averaged $414600.0.
  • As far as peak fluctuations go, Stoke Therapeutics' Capital Expenditures crashed by 9779.82% in 2024, and later soared by 116666.67% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Capital Expenditures (Quarter) stood at $409000.0 in 2022, then tumbled by 44.01% to $229000.0 in 2023, then tumbled by 81.66% to $42000.0 in 2024, then skyrocketed by 214.29% to $132000.0 in 2025.
  • Its last three reported values are $132000.0 in Q3 2025, $154000.0 for Q2 2025, and $152000.0 during Q1 2025.